State/Organization Pharmacopoeia Tender for Drug Products in India 2026 – USP/BP/EP Compliant, Make in India, 45 Day Delivery

Tender Overview

Organization/Entity has issued a pharmaceutical procurement tender for drug products requiring USP/BP/EP pharmacopoeia compliance, with multiple packaging specifications and dosage forms referenced in the data. The scope includes items across several product information categories, including drug name and labeling conformity, with a maximum delivery window of 45 days from order, and a potential quantity adjustment up to 25% as per the option clause. The tender emphasizes regulatory licenses, manufacturing authorizations, and Make in India certification, along with MSME eligibility where applicable. The data highlights emphasis on packaging standards, primary pack sizes, and labeling conformity, with an inspection regime on delivery to verify batch COA and licenses. This procurement appears to target suppliers capable of meeting strict pharmacopoeia and labeling requirements, including shelf-life considerations. The unique clauses drive compliance with regulatory documentation and post-award verifications, ensuring product traceability and regulatory alignment in pharmaceutical supply. The opportunity hinges on strict quality and regulatory adherence, with supplier readiness to supply within the extended delivery framework and to submit notarized undertakings as part of bid submissions.

Technical Specifications & Requirements

• Standards: Items must comply with USP/BP/EP pharmacopoeia standards.
• Documentation: Certificates of Analysis (COA) for each batch; valid manufacturing licenses; Make in India certificate; MSME certificate if applicable.
• Shelf Life Rule: Drugs with shelf life ≤2 years must have remaining shelf life at delivery; >2 years must have at least 1/3 of shelf life remaining at delivery.
• Delivery: Maximum delivery period specified as 45 days, with delivery extensions calculable per option clause.
• Labeling/Packaging: Products to conform to packaging, labeling, and storage requirements; logos and branding as applicable.
• Inspection: Items inspected on delivery; discrepancies may lead to rejection; price breakdowns may be requested.
• ATC/Compliance: Bidder must provide drug manufacturing licenses and other regulatory documents; notarized undertaking format required.
• Make in India: Certificates to be submitted; regulatory compliance is mandatory.
• BOQ: No typical line-item BOQ; focus on compliance and regulatory readiness.
• Other: Drug name and medicine name fields indicate product-level specificity expected in submissions.

Terms, Conditions & Eligibility

• EMD/Compliance: Specific EMD amount not disclosed in data; bidders must meet general tender security expectations and compliance checks.
• Delivery Term: Delivery window not-to-exceed 45 days from order date; extension mechanisms defined by option clause with quantity adjustments up to 25%.
• Documentation: Submit GST registration, PAN, experience certificates, manufacturing licenses, COA, Make in India and MSME certificates where applicable.
• Notarized Undertaking: Required format to be uploaded with bid; compliance with five-day submission window is referenced.
• Inspection: Delivered items will undergo inspection; discrepancies may result in rejection.
• Payment Terms: Not explicitly stated in data; bidders should prepare for standard pharma procurement terms.
• Brand/OEM/Labels: Labels and logos must align with regulatory expectations; conformity to packaging standards is mandatory.
• Regulatory: Adherence to pharmacopeia standards, labeling, storage, and documentation compliance is essential.
• Special Clauses: Make in India and MSME considerations, shelf-life compliance, and notarized undertaking are key differentiators.